Maheshi N Ramasamy
Overview
Explore the profile of Maheshi N Ramasamy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
6235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fidler S, Fox J, Tipoe T, Longet S, Tipton T, Abeywickrema M, et al.
Clin Infect Dis
. 2022 Oct;
76(2):201-209.
PMID: 36196614
Background: People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)....
12.
Shaw R, Liu X, Stuart A, Greenland M, Aley P, Andrews N, et al.
Lancet Respir Med
. 2022 Jun;
10(11):1049-1060.
PMID: 35690076
Background: Priming COVID-19 vaccine schedules have been deployed at variable intervals globally, which might influence immune persistence and the relative importance of third-dose booster programmes. Here, we report exploratory analyses...
13.
Ratcliff J, Al-Beidh F, Bibi S, Bonsall D, Clemens S, Estcourt L, et al.
J Clin Microbiol
. 2022 Mar;
60(4):e0228321.
PMID: 35321556
Tools to detect SARS-CoV-2 variants of concern and track the ongoing evolution of the virus are necessary to support public health efforts and the design and evaluation of novel COVID-19...
14.
Ogbe A, Pace M, Bittaye M, Tipoe T, Adele S, Alagaratnam J, et al.
JCI Insight
. 2022 Feb;
7(7).
PMID: 35192543
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male...
15.
Stuart A, Shaw R, Liu X, Greenland M, Aley P, Andrews N, et al.
Lancet
. 2021 Dec;
399(10319):36-49.
PMID: 34883053
Background: Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19...
16.
Vesikari T, Finn A, Van Damme P, Leroux-Roels I, Leroux-Roels G, Segall N, et al.
JAMA Netw Open
. 2021 Oct;
4(10):e2128652.
PMID: 34636914
Importance: There is a need for improved immunogenicity of hepatitis B virus (HBV) vaccines among young adults with risk of infection. Objectives: To demonstrate manufacturing equivalence of a 3-antigen (3A)...
17.
Clemens S, Folegatti P, Emary K, Weckx L, Ratcliff J, Bibi S, et al.
Nat Commun
. 2021 Oct;
12(1):5861.
PMID: 34615860
Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19...
18.
Flaxman A, Marchevsky N, Jenkin D, Aboagye J, Aley P, Angus B, et al.
Lancet
. 2021 Sep;
398(10304):981-990.
PMID: 34480858
Background: COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between the first and second dose becomes longer. Conversely, countries with no supply...
19.
Liu X, Shaw R, Stuart A, Greenland M, Aley P, Andrews N, et al.
Lancet
. 2021 Aug;
398(10303):856-869.
PMID: 34370971
Background: Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter...
20.